EMA continues to review link between myocarditis and coronavirus vaccination
The European Medicines Agency needs more data before arriving at a conclusion on whether inflammation of the heart muscle is a possible side effect of coronavirus vaccines.
BY ULRICH QUISTGAARD, TRANSLATED BY NIELSINE NIELSEN
The Pharmacovigilance Risk Assessment Committee (PRAC) at the European Medicines Agency (EMA) will keep reviewing reports on pericarditis and myocarditis following vaccination with Johnson & Johnson's covid-19 vaccine. PRAC concludes that more data and investigation will be needed in order to assess whether there is a documented connection between cause and effect, according to the Danish Medicines Agency (DMA).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian Nordic to supply UK with monkeypox vaccines
For subscribers
